An additional risk model PRG based on more immune-related genes (CASP4, GSDMC, IL-18, NLRP1, NLRP2, PLCG1, TIRAP, and TNF) was developed, which can be used to predict pancreatic cancer prognosis with an accuracy of medium to high. This evidence concerns the gene NLRP2 and familial pancreatic carcinoma.